Literature DB >> 11839153

CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates.

Andreas Mörner1, Asa Björndal, Ann-Charlotte Leandersson, Jan Albert, Ewa Björling, Marianne Jansson.   

Abstract

Primary human immunodeficiency virus type 2 (HIV-2) isolates are characterized by their ability to use a broad range of coreceptors, including CCR5, CXCR4, and several alternative coreceptors. However, the in vivo relevance of this in vitro promiscuity in coreceptor usage remains unclear. We set out to evaluate the relative importance of CCR5 and CXCR4 for infection of activated peripheral blood mononuclear cells (PBMC). PBMC from donors homozygous for wild-type CCR5 (CCR5(+/+) or CCR5Delta32 (CCR5(-/-)) were tested for their susceptibility to infection with 10 primary HIV-2 isolates with known coreceptor usage by parallel 50% tissue culture infectious dose (TCID50) titrations. Although all isolates, except one, were able to establish productive infection in CCR5(-/-) PBMC, the infection of these cells was inefficient for all isolates that were unable to use CXCR4. For CXCR4-using isolates there were only minor differences in TCID50 between CCR5(+/+) and CCR5(-/-) PBMC. When we compared the replication kinetics in PBMC from donors of the two genotypes we observed an average delay in replication onset of 9 days in the CCR5(-/-) PBMC. This study shows that HIV-2 can use alternative coreceptors for infection of PBMC, but that this infection is much less efficient than infection mediated by CCR5 or CXCR4. Thus, CCR5 and CXCR4 appear to be the major coreceptors for HIV-2 infection of PBMC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839153     DOI: 10.1089/08892220252781248

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia.

Authors:  H Blaak; P H M Boers; R A Gruters; H Schuitemaker; M E van der Ende; A D M E Osterhaus
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection.

Authors:  Rui Soares; Russell Foxall; Adriana Albuquerque; Catarina Cortesão; Miguel Garcia; Rui M M Victorino; Ana E Sousa
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

4.  HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs.

Authors:  Zsófia Ilona Szojka; Sara Karlson; Emil Johansson; Gülşen Özkaya Şahin; Marianne Jansson
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

5.  A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.

Authors:  Matthias Döring; Pedro Borrego; Joachim Büch; Andreia Martins; Georg Friedrich; Ricardo Jorge Camacho; Josef Eberle; Rolf Kaiser; Thomas Lengauer; Nuno Taveira; Nico Pfeifer
Journal:  Retrovirology       Date:  2016-12-20       Impact factor: 4.602

6.  Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Authors:  Benoit Visseaux; Charlotte Charpentier; Gilles Collin; Mélanie Bertine; Gilles Peytavin; Florence Damond; Sophie Matheron; Eric Lefebvre; Françoise Brun-Vézinet; Diane Descamps
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.